Advertisement

Allogeneic haematopoietic stem cell transplantation with myeloablative conditioning for adult cerebral X-linked adrenoleukodystrophy

  • Nils Waldhüter
  • Wolfgang Köhler
  • Philipp G. Hemmati
  • Christian Jehn
  • Rudolf Peceny
  • Giang L. Vuong
  • Renate Arnold
  • Jörn-Sven KühlEmail author
Original Article

Abstract

The adult cerebral form of X-linked adrenoleukodystrophy (ACALD), an acute inflammatory demyelinating disease, results in a rapidly progressive neurodegeneration, typically leading to severe disability or death within a few years after onset. We have treated 15 men who had developed ACALD with allogeneic haematopoietic stem cell transplantation (HSCT) from matched donors after myeloablative conditioning with busulfan and cyclophosphamide. All patients engrafted and 11 survived (estimated survival 73 ± 11%), eight with stable cognition and seven of them with stable motor function (estimated event-free survival 36 ± 17%). Death after transplantation occurred within the first year after HSCT and was caused either primarily by infection (n = 3) or due to disease progression triggered by infection (n = 1). Patients with minor myelopathic symptoms (n = 4) or with no or mild cerebral symptoms pre-transplant (n = 7) had an excellent outcome. In contrast, no patient with major neurological symptoms associated with an extensive involvement of pyramidal tract fibres in the internal capsule (n = 5) survived without cognitive deterioration. Notably, early leukocyte recovery was associated with dismal outcome for yet unknown reasons. All ten tested survivors showed a reduction of plasma hexacosanoic acid (C26:0) in the absence of Lorenzo’s oil. Over time, the event-free survival could be improved from 2 out of 8 patients (25%) before 2013 to 5 out of 7 patients (71%) thereafter. Therefore, allogeneic HSCT appears to be a suitable treatment option for carefully selected ACALD patients when transplanted from matched donors after myeloablative, busulfan-based conditioning.

Keywords

X-linked adrenoleukodystrophy Adult cerebral ALD Haematopoietic stem cell transplantation Myeloablative conditioning Magnetic resonance imaging Internal capsule 

Abbreviations

AACS

Adult ALD Clinical Score

ACALD

Adult cerebral ALD

ALD

Adrenoleukodystrophy

AMN

Adrenomyeloneuropathy

ATG

Anti-thymocyte globulin

BM

Bone marrow

CCALD

Childhood cerebral ALD

EDSS

Kurtzke Expanded Disability Status Scale

G-CSF

Granulocyte colony-stimulating factor

GVHD

Graft-versus-host disease

HSCT

Haematopoietic stem cell transplantation

MRI

Magnetic resonance imaging

PBSC

Peripheral blood stem cells

VLCFA

Very long chain fatty acids

X-ALD

X-linked ALD

Notes

Acknowledgements

We are indebted to PD Dr. M. Nagy, Berlin, for the laboratory expertise in performing DNA chimerism and to Dr. rer. nat. D. Hunneman, Göttingen, for measuring VLCFA in plasma.

We thank the non-profit organisations Myelin Project, Germany, ELA Germany, StopALD, USA, and ALD Charity, Switzerland for encouraging and supporting patients and families.

Funding

No specific funding to report.

Compliance with ethical standards

Conflict of interest

Wolfgang Köhler, Christian Jehn and Renate Arnold have no conflict of interest.

Nils Waldhüter has received a travel grant from Pfizer.

Philipp G. Hemmati has received a travel grant from Neovii.

Rudolf Peceny has received a travel grant from Sanofi.

Giang L. Vuong has received travel grants from Celgene and Gilead.

Jörn-Sven Kühl has received honoraria from bluebird bio and a travel grant from Neovii.

Supplementary material

10545_2018_241_MOESM1_ESM.doc (44 kb)
ESM 1 (DOC 44 kb)

References

  1. Aubourg P, Blanche S, Jambaqué I et al (1990) Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 322:1860–1866CrossRefPubMedGoogle Scholar
  2. Ben-Barouch S, Cohen O, Vidal L, Avivi I, Ram R (2016) Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transplant 51:232–240CrossRefPubMedGoogle Scholar
  3. Berger J, Forss-Petter S, Eichler FS (2014) Pathophysiology of X-linked adrenoleukodystrophy. Biochimie 98(100):135–142CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bertz H, Potthoff K, Mertelsmann R, Finke J (1997) Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 19:1169–1173CrossRefPubMedGoogle Scholar
  5. Capotondo A, Milazzo R, Politi LS et al (2012) Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. Proc Natl Acad Sci U S A 109:15018–15023CrossRefPubMedPubMedCentralGoogle Scholar
  6. Cartier N, Lewis CA, Zhang R, Rossi FM (2014) The role of microglia in human disease: therapeutic tool or target? Acta Neuropathol 128:363–380CrossRefPubMedPubMedCentralGoogle Scholar
  7. de Beer M, Engelen M, van Geel BM (2014) Frequent occurrence of cerebral demyelination in adrenomyeloneuropathy. Neurology 83:2227–2231CrossRefPubMedGoogle Scholar
  8. Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945–956CrossRefPubMedGoogle Scholar
  9. Fitzpatrick AS, Loughrey CM, Johnston P et al (2008) Haematopoietic stem-cell transplant for adult cerebral adrenoleukodystrophy. Eur J Neurol 15:e21–e22CrossRefPubMedGoogle Scholar
  10. Gong Y, Sasidharan N, Laheji F et al (2017) Microglial dysfunction as a key pathological change in adrenomyeloneuropathy. Ann Neurol 82(5):813–827CrossRefPubMedPubMedCentralGoogle Scholar
  11. Hitomi T, Mezaki T, Tomimoto H et al (2005) Long-term effect of bone marrow transplantation in adult-onset adrenoleukodystrophy. Eur J Neurol 12:807–810CrossRefPubMedGoogle Scholar
  12. Holtick U, Albrecht M, Chemnitz JM et al (2015) Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis. Crit Rev Oncol Hematol 94:179–188CrossRefPubMedGoogle Scholar
  13. Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448–457CrossRefPubMedGoogle Scholar
  14. Kemp S, Berger J, Aubourg P (2012) X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta 1822:1465–1474CrossRefPubMedGoogle Scholar
  15. Köhler W (2010) Leukodystrophies with late disease onset: an update. Curr Opin Neurol 23(3):234–241CrossRefPubMedGoogle Scholar
  16. Köhler W, Sokolowski P (1999) A new disease-specific scoring system for adult phenotypes of x-linked adrenoleukodystrophy. J Mol Neurosci 13:247–252CrossRefGoogle Scholar
  17. Kühl JS, Suarez F, Gillett GT et al (2017) Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy. Brain 140:953–966CrossRefPubMedGoogle Scholar
  18. Kühl JS, Kupper J, Baqué H et al (2018) Potential risks to stable long-term outcome of allogeneic hematopoietic stem cell transplantation for children with cerebral X-linked adrenoleukodystrophy. JAMA Network Open 1:e180769CrossRefGoogle Scholar
  19. Loes DJ, Hite S, Moser H et al (1994) Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol 15:1761–1766PubMedGoogle Scholar
  20. López-Erauskin J, Galino J, Ruiz M et al (2013) Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. Hum Mol Genet 22(16):3296–3305CrossRefPubMedGoogle Scholar
  21. Miller WP, Rothman SM, Nascene D et al (2011) Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood 118:1971–1978CrossRefPubMedGoogle Scholar
  22. Moser HW (1997) Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120(Pt 8):1485–1508CrossRefPubMedGoogle Scholar
  23. Moser HW, Mahmood A (2007) New insights about hematopoietic stem cell transplantation in adrenoleukodystrophy. Arch Neurol 64:631–632CrossRefPubMedGoogle Scholar
  24. Peters C, Charnas LR, Tan Y et al (2004) Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 104:881–888CrossRefPubMedGoogle Scholar
  25. Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825–828PubMedGoogle Scholar
  26. Remberger M, Törlén J, Ringdén O et al (2015) Effect of total nucleated and CD34(+) cell dose on outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21:889–893CrossRefPubMedGoogle Scholar
  27. Semmler A, Köhler W, Jung HH, Weller M, Linnebank M (2008) Therapy of X-linked adrenoleukodystrophy. Expert Rev Neurother 8(9):1367–1379CrossRefPubMedGoogle Scholar
  28. Shapiro E, Krivit W, Lockman L et al (2000) Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 356:713–718CrossRefPubMedGoogle Scholar
  29. Socié G, Schmoor C, Bethge WA et al (2011) Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 117:6375–6382CrossRefPubMedGoogle Scholar
  30. Turk BR, Moser AB, Fatemi A (2017) Therapeutic strategies in adrenoleukodystrophy. Wien Med Wochenschr 167:219–226CrossRefPubMedGoogle Scholar
  31. Tvedt TH, Lie SA, Reikvam H et al (2016) Pretransplant levels of CRP and interleukin-6 family cytokines; effects on outcome after allogeneic stem cell transplantation. Int J Mol Sci 17. pii: E1823Google Scholar
  32. van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV (2001) Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 49:186–194CrossRefPubMedGoogle Scholar
  33. Weber FD, Wiesinger C, Forss-Petter S et al (2014) X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes. Hum Mol Genet 23:2542–2550CrossRefPubMedGoogle Scholar
  34. Weinhofer I, Zierfuss B, Hametner S et al (2018) Impaired plasticity of macrophages in X-linked adrenoleukodystrophy. Brain.  https://doi.org/10.1093/brain/awy127

Copyright information

© SSIEM 2018

Authors and Affiliations

  1. 1.Department Hematology, Oncology and TumorimmunologyCharité Campus Virchow-KlinikumBerlinGermany
  2. 2.Department NeurologyUniversitätsklinikum LeipzigLeipzigGermany
  3. 3.Department Oncology/Hematology/SCTKlinikum OsnabrückOsnabrückGermany
  4. 4.Department Pediatric Oncology/Hematology/SCTCharité Campus Virchow-KlinikumBerlinGermany
  5. 5.Department Pediatric Oncology/Hematology/HemostasealogyUniversitätsmedizin LeipzigLeipzigGermany

Personalised recommendations